MISSION VIEJO, CA--(Marketwired - March 15, 2017) -
-
TREATMENT WITH AEOL 20415 REDUCED INFECTION, IMPROVED BODY WEIGHT AND REDUCED PRESENCE OF WHITE BLOOD CELLS, MACROPHAGES AND LYMPHOCYTES
-
DETAILED RESULTS TO BE SUBMITTED FOR PUBLICATION
Aeolus Pharmaceuticals, Inc. (AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced that a study completed at National Jewish Health showed that AEOL 20415 protects the lungs in a mouse model of cystic fibrosis. The studies were performed by Brian Day, PhD, Vice Chair of Research at National Jewish Health. Aeolus is a biotechnology company focused on developing compounds to address unmet medical needs in both traditional as well as governmental markets. AEOL 20415 has demonstrated potential as both a treatment for cystic fibrosis as well as antibiotic-resistant bacteria. Development of novel treatments for antibiotic-resistant bacteria has been a major priority at both the National Institutes of Health ("NIH") and the Biomedical Advanced Research and Development Authority ("BARDA").
"This study confirms previous in-vitro studies indicating that AEOL 20415 is unique because it augments the body's natural host defense system for fighting bacterial infection while limiting inflammation," stated Brian Day, PhD, Vice Chair of Research at National Jewish Health. "Currently available anti-inflammatory drugs work by suppressing the immune system, which can be counterproductive during active infection. AEOL 20415 has demonstrated efficacy in killing drug resistant clinical strains of Burkholderia cepacia and Pseudomonas aeruginosa isolated from cystic fibrosis patients and improving bacterial clearance while diminishing lung inflammation."
Aeolus believes that AEOL 20415 may have applications as a broad spectrum anti-microbial and in several large medical indications. As an anti-microbial, the compound has demonstrated the ability to kill pathogens, including antibiotic-resistant strains, while dampening inflammation caused by immune response to both viral and bacterial infections. In some infectious diseases, such as virulent strains of influenza virus, inflammation from the body's normal immune response can increase lethality. Aeolus believes that the combination of anti-microbial and anti-inflammatory activity exhibited by the new compounds could be particularly beneficial in treating these types of infectious threats.
"AEOL 20415 shows tremendous promise as both a potential treatment for cystic fibrosis and as a solution to the growing problem of drug-resistant bacteria. We look forward to sharing this animal data with potential collaborators in industry and the government in our continuing efforts to address unmet medical needs through public-private partnerships, such as those we have used to develop our lead compound AEOL 10150," said John McManus, Chief Executive Officer of Aeolus. "The combination of anti-microbial and anti-inflammatory action of AEOL 20415 makes it particularly effective in addressing antibiotic-resistant infectious disease threats, as well traditional indications like cystic fibrosis."